Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate L9LS in Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
INCLUSION CRITERIA:~A volunteer must have met all of the following criteria to be included:~1. Able and willing to complete the informed consent process~2. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process~3. Available for clinical follow-up through the last study visit~4. 18 to 50 years of age~5. In good general health without clinically significant medical history~6. Physical examination without clinically significant findings within the 56 days prior to enrollment~7. Weight \<= 115 kg (except Group 5)~8. Adequate venous access if assigned to an IV group or adequate subcutaneous tissue if assigned to an SC group~9. Willing to have blood samples collected, stored indefinitely, and used for research purposes~10. Agrees to participate in a controlled human malaria infection (CHMI) and to comply with post-CHMI follow-up requirements (except Group 6)~11. Agrees to refrain from blood donation to blood banks for 3 years following participation in CHMI (except Group 6)~12. Agrees not to travel to a malaria endemic region during the entire course of study participation (except Group 6)~    Laboratory Criteria within 56 days prior to enrollment:~13. White Blood Cell (WBC) 2,500-12,000/mm\^3~14. WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval~15. Platelets = 125,000-500,000/mm\^3~16. Hemoglobin within institutional normal range or accompanied by the PI or designee approval~17. Creatinine \<= 1.1 x upper limit of normal (ULN)~18. Alanine aminotransferase (ALT) \<=1.25 x ULN~19. Negative for HIV infection by an FDA approved method of detection~    Laboratory Criteria documented any time during screening, prior to enrollment:~20. Negative polymerase chain reaction (PCR) for malaria (except Group 6)~21. Negative sickle cell screening test (except Group 6)~22. Electrocardiogram (ECG) without clinically significant abnormalities (examples may include: pathologic Q waves, significant ST-T wave changes, left ventricular hypertrophy, any non-sinus rhythm excluding isolated premature atrial contractions, right or left bundle branch block, advanced A-V heart block). ECG abnormalities determined by a cardiologist to be clinically insignificant as related to study participation do not preclude study enrollment (except Group 6)~23. No evidence of increased cardiovascular disease risk; defined as \>10% five-year risk by the non-laboratory method (except Group 6)~    Criteria Specific to Women:~24. Postmenopausal for at least 1 year, post-hysterectomy or bilateral oophorectomy, or if of childbearing potential:~    1. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on day of enrollment, and prior to product administration and CHMI, and~   2. Agrees to use an effective means of birth control through the duration of study participation~EXCLUSION CRITERIA:~A volunteer would have been excluded if one or more of the following conditions applied:~1. Woman who is breast-feeding or planning to become pregnant during study participation~2. Previous receipt of a malaria vaccine or anti-malaria monoclonal antibody~3. History of malaria infection~4. Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the study~5. Hypertension that is not well controlled~6. Receipt of any investigational study product within 28 days prior to enrollment/product administration (Note: SARS-CoV-2 vaccines approved by emergency use authorization are not exclusionary)~7. Receipt of any live attenuated vaccines within 28 days prior to enrollment/product administration~8. Receipt of any vaccine within 2 weeks prior to enrollment/product administration~9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular injections or blood draws~10. History of a splenectomy, sickle cell disease or sickle cell trait~11. History of skeeter syndrome or anaphylactic response to mosquito-bites (except Group 6)~12. Known intolerance to chloroquine phosphate, atovaquone or proguanil (except Group 6)~13. Use or planned use of any drug with antimalarial activity that would coincide with study product or CHMI (except Group 6)~14. History of psoriasis or porphyria, which may be exacerbated after treatment with chloroquine (except Group 6)~15. Anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and kaolin~16. History of Sjogren's Syndrome~17. History of chronic or recurrent salivary gland disorder diagnosed by a clinician (note: an isolated occurrence of parotitis, sialadenitis, sialolithiasis, or of a salivary gland tumor is not exclusionary)~18. History of therapeutic head or neck radiation~19. Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, infectious diseases, psychiatric disorders, heart disease, or cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: L9LS (1 mg/kg IV) (Type: EXPERIMENTAL): L9LS (1 mg/kg) administered by intravenous (IV) infusion (Day 0)
- Group 2: L9LS (5 mg/kg IV) (Type: EXPERIMENTAL): L9LS (5 mg/kg) administered by IV infusion (Day 0)
- Group 3: L9LS (5 mg/kg SC) (Type: EXPERIMENTAL): L9LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
- Group 4: L9LS (20 mg/kg IV) (Type: EXPERIMENTAL): L9LS (20 mg/kg) administered by IV infusion (Day 0)
- Group 5: CHMI Controls (Type: OTHER): Control participants who did not receive L9LS and were enrolled to complete the controlled human malaria infection (CHMI)
- Group 6: L9LS (5 mg/kg IM) (Type: EXPERIMENTAL): L9LS (5 mg/kg) administered by intramuscular (IM) injection (Day 0)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete